Arthur T. Armstrong, Jr., MD, PhD

Contact Info

1900 Polaris Pkwy Suite 450-153

Columbus, Ohio 43240

Phone: 740-513-9933

arthurarmstrong@hotmail.com

**CURRENT OCCUPATION**

Medical Consulting of health devices and therapies

**EDUCATION**

2005-2007 Rheumatology Fellowship, Geisinger Medical Center, Danville, PA

2001–2005 Combined Residency in Medicine/Pediatrics, Geisinger Medical Center

1997-2001 MD, St. George’s University School of Medicine, Grenada

* 1. PhD, Ohio State University: Dept of Cell Biology, Neurobiology and Anatomy

1986-1990 BS, Muskingum College: Biology

**EMPLOYMENT**

2013-2022 Arthritis Solutions Rheumatology Practice and Infusion Center- **Owner and Rheumatologist**

Practice and Infusion Center sold 2022.

2012-2013Ohio Health-Marion Area Physicians- **Rheumatologist**

Elected Member on MAP Board of Physicians

2007-2012 Smith Clinic Multispecialty Group- **Rheumatologist, Shareholder**

2008-2023 **Pharmaceutical Industry Speaker** for various companies including Pfizer, Genentech,

Horizon, Exagen, and GlaxoSmithKline.

1996-1997 **Post-doctoral Research Associate**, Ohio State University, Dept of Cardiology.

**TEACHING**

2021 **Preceptor**, University of Cincinnati College of Nursing. Clinical training of muscular skeletal

Disease

1991-1995 **Teaching Assistant**, Ohio State University Dept of Cell Biology, Neurobiology and

Anatomy. Teaching Anatomy and Cellular Biology to graduate and undergraduate students.

**CLINICAL TRIAL RESEARCH** **AT GEISINGER MEDICAL CENTER**

A Randomized, Double-Blind, Placebo-controlled, Parallel Group Study of the Safety and Reduction of Signs and Symptoms during Treatment with MRA Versus Placebo, in Combination with Methotrexate in Patients with Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Previous Anti-TNF Therapy 2005- 2006. Principal Investigator- Thomas Harrington MD

Sub-Investigators- Newman, Perruquet, Olenginski, Llinas, Santhi, Pugliese, Armstrong

Consortium of Rheumatology Researchers of North America (CORRONA) Functional Outcomes Questionnaire to Assess Status of Patients with Rheumatic Disease in the Clinic 2001- 2006

Principal Investigator - Eric D Newman MD

Sub-Investigators- Harrington, Perruquet, Olenginski, Davis, Torretti, Ayoub, Nowak, Mucciolo, Saripalli, Ramos, Llinas, Santhi, Pugliese, Armstrong

Treatment of Rheumatoid Arthritis with Borage Oil and Fish Oil 2004- 2006.

Principal Investigator - Eric D Newman MD

Sub-Investigators- Harrington, Perruquet, Olenginski, Llinas, Santhi, Pugliese, Armstrong

FORTEO Observational Study (DANCE) 2005- present. Principal Investigator- Eric Newman MD

Sub-Investigators- Harrington, Perruquet, Olenginski, Llinas, Santhi, Pugliese, Armstrong

A Randomized, Double-Blind, Parallel Group Study Of The Safety And Prevention Of Structural Joint Damage During Treatment With MRA Versus Placebo, In Combination With Methotrexate, In Patients With Moderate To Severe Active Rheumatoid Arthritis 2004- 2006. Principal Investigator- Thomas Olenginski MD

Sub-Investigators- Newman, Harrington, Perruquet, Llinas, Santhi, Pugliese, Armstrong

A Multi-center, Randomized, Double-Blind, Active-Controlled Study Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis Subjects Who Are Sub-optimal Responders to Etanercept 50 mg Once Weekly (QW) 2005- 2006. Principal Investigator- James Perruquet MD

Sub-Investigators- Newman, Harrington, Olenginski, Llinas, Santhi, Pugliese, Armstrong

**Clinical Research at Arthritis Solutions**

Primary Investigator: Corrona (Corevista) RA and PsA Registry Database Studies: 2020-2022

Sub-Investigator: Julia Hypes, CNP

**PUBLICATIONS**

Petrosino S, Armstrong AT, Matende B. Disease Severity, Oxidative Stress, and Hyper-inflammatory induction in SARS-cov-2 as a Basis for Dietary, Pharmacologic, and Herbal Intervention in the Prevention, Management, and Treatment of COVID-19: A Scoping Review J of Community Medicine and Public Health Reports. June 2021:2(9)

Armstrong AT, Tyler WB, Wood GC, Harrington TM. Clinical importance of the presence of giant cells in temporal arteritis. J of Clinical Path. March 2008:61;669-71.

Armstrong AT, Binkley P, Baker P, Leier CV. Histologic comparison of allograft myocardium between short and

long term survivors of human cardiac transplantation. Am J Cardiology. Nov 2000:86;148-51.

Armstrong AT, Binkley P, Baker P, Myerwitz P, Leier CV. Quantitative investigation of cardiomyocyte

hypertrophy and myocardial fibrosis over 6 years after cardiac transplantation. J Am Coll. of Cardiology. Sept

1998:32(3);704-10.

Strauch A, Cogan J, Subramanian S, Armstrong A, Sun S, Getz M. Transcriptional activity of the vascular

alpha-actin gene as an indicator of cellular injury following cardiac transplant. Transplant Immunology. Dec

1997:5(4);261-6.

Armstrong AT, Strauch A, Starling RC, Sedmak DD, Orosz C. Morphometric analysis of neointimal formation in murine cardiac grafts III. Transplantation. Oct 1997;64(8):1198-202.

II. Transplantation. July 1997:64(2):322-8.

I. Transplantation. April 1997:63(7):941-947.

Armstrong AT, Strauch A, Kardan A, Starling RC. Morphometric and immunocytochemical analysis of coronary arterioles in human transplanted hearts. J of Heart and Lung Transplantation. Aug. 1996:15(8);818-26.

**PRESENTATIONS**

Monthly presenter at Sourcepoint Delaware County Senior Center 2013-2022

Regular community lectures in Central Ohio for Arthritis Foundation 2008 –2012

Am. Soc. of Transplantation. Physicians Meeting- Chicago, IL 5/95: Poster presentation.

International Symposium on Transplant Vascular Sclerosis- Bermuda 4/95: Poster presentation.

Am. Federation for Clinical Research Convention- Chicago, IL 8/94: Slide show presentation.

Am Coll of Rheumatology National Meeting- Washington DC, 11/2006. Poster presentations.

Clinical Differences of Giant Cell Arteritis versus Non-Giant Cell Arteritis Patients Who were Diagnosed by

Temporal Artery Biopsy

Prognostic significance of Creatine Kinase (CK) levels in Dermatomyositis.